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The  Institute  of Vaccines  and  Medical  Biologicals  (IVAC),  a state-owned  vaccine  manufacturer,  initiated
research  into  avian  inﬂuenza  vaccines  in  the  early  1990s  in  response  to the  threat  of a highly  pathogenic
avian  inﬂuenza  pandemic.  Successful  results  from  laboratory  studies  on  A(H5N1)  inﬂuenza  virus  attracted
seed  funds  and  led  to  participation  in  the  WHO  technology  transfer  project  to  enhance  inﬂuenza  vaccine
production  in developing  countries.  IVAC’s  goal  is to produce  500,000  doses  of  inactivated  monovalent
whole-virion  inﬂuenza  vaccine  per  year  by 2012,  and  progressively  increase  capacity  to  more  than  1
million  doses  to  protect  essential  populations  in  Viet  Nam  in the  event  of  an  inﬂuenza  pandemic.  The
WHO  seed  grants,  supplemented  by  other  international  partner  support,  enabled  IVAC to build  in a very
short  time  an  inﬂuenza  vaccine  manufacturing  plant  under  Good  Manufacturing  Practice  and  relevant
biosafety  standards,  a waste  treatment  system  and  a dedicated  chicken  farm  for high-quality  eggs.  Much
of  the  equipment  and  instrumentation  required  for vaccine  production  has  been  installed  and  tested  for
functional  operation.  Staff  have  been  trained  on  site and  at specialized  courses  which  provided  com-
prehensive  manuals  on  egg-based  manufacturing  processes  and  biosafety.  Following  process  validation,
clinical  trials  will start  in  2011  and  the  ﬁrst domestic  inﬂuenza  vaccine  doses  are  expected  in  2012.. Introduction
Viet Nam has been committed to inﬂuenza pandemic pre-
aredness ever since a highly pathogenic avian inﬂuenza virus
it animal and human populations in Asia in 1990s. At that
ime, scientists from the Institute of Biotechnology pioneered
he production of poultry vaccines against H5N1, which enabled
he country to reduce dramatically avian and human disease
ncidence. In 2005, the Government of Viet Nam developed a
ational plan for human inﬂuenza vaccine production, within
hich the state-owned Institute of Vaccines and Medical Bio-
ogicals (IVAC) undertook preliminary research on egg-derived
nactivated inﬂuenza vaccine A(H5N1) with positive laboratory
esults. These results, and strong domestic backing, encouraged
VAC to seek support to extend this research. Seed funding was
ound and IVAC was selected in 2007 as a grantee of the World
ealth Organization (WHO) pandemic inﬂuenza vaccine technol-
gy transfer initiative.
The  goal of IVAC is to manufacturer 500,000 doses of monovalent
nﬂuenza vaccine under appropriate biosafety and current Good
anufacturing Practice (cGMP) conditions, with the potential for
xpansion to >1 million doses per year. The speciﬁc objectives are
o build and equip a small-scale manufacturing facility to produce
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egg-derived inactivated whole virion, alum adjuvanted inﬂuenza
vaccine for pandemic use, complemented by a waste treatment
system and a chicken farm to secure supplies of qualiﬁed clean
eggs. Progress towards these objectives in 2008–2010 is described
below.
2. Inﬂuenza manufacturing plant
Following evaluation of the dossier by WHO  in May  2008 and
a national tender process, a contractor was  selected to design and
construct a dedicated inﬂuenza vaccine production plant with a
waste treatment system near IVAC in Nha Trang. In record speed,
this facility was  completed, certiﬁed cGMP-compliant and since
June 2010 has been undergoing test operations within a validation
programme. Much of the critical facility and process equipment has
been procured and controlled for installation, operation, perfor-
mance and maintenance qualiﬁcation. The Master Validation Plan
for inﬂuenza vaccine production was approved which contains the
strategy for the validation of processes based on risk assessment,
focusing primarily on sterility and viral safety.
To increase production capacity to at least 1 million doses per
year, IVAC installed hot and cold rooms in a dedicated space, more
incubator equipment and separate zones for in-process testing and
Open access under CC BY-NC-ND license.the preparation of media and cleaning of equipment; inoculation
and harvesting; and puriﬁcation. Independent technical units have
been set up to serve as a contaminated area, a noncontaminated
area, and egg-handling and entrance, respectively. Each area is
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Table 1
Projected timeline to manufacture pandemic inﬂuenza vaccine.
Activity Expected completion
Remaining critical equipment for validation
procured
December 2010
Maintenance instruments and standards
functional
December 2010
Quality eggs available from IVAC chicken farm February 2011
Manufacturing standard operating procedures
and master batch records validated
February 2011
Environmental programme for air and water
fully operational
February 2011
Cleaning programme validated February 2011
All  training documented March 2011
Performance qualiﬁcation documents for all
systems completed and approved with
successful pre-licensure audit report
April 2011
Production of 3 consecutive lots for clinical
trials initiated
June  2011
Good Laboratory Practice nonclinical
toxicology studies completed
December 2011
Phase  I clinical trials completed March 2012
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HPhase II clinical trials completed July 2012
Licensing process initiated for H1N1 and H5N1 December 2012
nstalled with separate heating, ventilation and air-conditioning
HVAC) systems. The HVAC systems and clean rooms have been
ualiﬁed using a series of manufacturing runs, constant control
f environmental conditions and digital direct controller system
o stabilize room temperature, pressure and humidity. The quality
ontrol laboratory has been upgraded to meet international stan-
ards for inﬂuenza vaccine production and ancillary zones have
een created for personnel.
The  waste treatment system has been installed with high efﬁ-
iency particulate air ﬁlters in outgoing airﬂows. Contaminated
uids from the production process are steam-sterilized before
ending to the central ﬂuid waste treatment station, and con-
aminated egg waste is kept in special bins for incineration after
econtamination. A two-door autoclave for decontamination is in
lace, and a kill tank pressure vessel has been ordered, where liq-
ids for decontamination will be collected and heated to 60–80 ◦C
efore disposal.
Standard operating procedures have been prepared for the
peration and maintenance of each piece of equipment. IVAC is
mplementing an environmental control programme for air quality
hich meets particulate and microbiological speciﬁcations. Sys-
ems to ensure puriﬁed water and water for injection will become
ully operational in 2011 (see Table 1).
. Process validation batches
Onset of the A(H1N1) inﬂuenza pandemic in 2009 switched
he focus from (A)H5N1 to the novel pandemic strain. Eight ini-
ial batches of H1N1 inﬂuenza whole virion vaccine were produced
t a scale of 7000 eggs and used to test and improve the perfor-
ance of the production process equipment and enhance the skills
f IVAC staff. The ﬁrst batch was produced with assistance from
he Netherlands Vaccine Institute (NVI) and all process steps were
valuated. Valuable recommendations from international partners
able 2
arvesting performance based on a volume from 4 trays with 36 eggs: optimal correlatio
Test Nozzle depth (mm)  Vacuum (times) Bottle full (
3 42  4 3225.0 
1  44 4 3301.8 
2  44 6 3744.6 
4 46  4 3685.8 
5  48 4 3778.9 S (2011) A34– A36 A35
were  immediately implemented to ensure that the next batches
were improved. Optimal growth conditions were established and
calibration procedures provided evidence for an inoculation dose
of 0.16–0.24 ml  per egg. Operators also became skilled in decapping
and harvesting, clariﬁcation and ﬁltration, zonal centrifugation and
calibration to meet containment, biosafety and GMP  standards.
Optimal conditions for manual decapping are ongoing and have
led to a reduction in the number of broken eggs. To optimize the
harvester settings, the measurement for a harvested volume from
4 trays of 36 eggs was performed (Table 2). The Beta proprio lacton
(BPL) method is now used for the inactivation process following
a training course for IVAC staff at NVI in June 2010 and receipt
of validation procedures. Corrective action also led to signiﬁcant
improvement in the evaluation of optical density and bioburden.
The experience of this series of manufacturing runs of increasing
size and complexity will allow IVAC to be able to perform success-
fully full-scale manufacturing lots. The performance qualiﬁcation
of all items, test runs and optimization of processes are expected
to be completed by the end of 2010. After process validation runs,
IVAC will produce three consecutive lots for preclinical trial and
testing at IVAC, the National Institute for Control of Vaccine and
Biologicals and international laboratories.
4. Chicken farm
In  order to secure eggs of consistent high quality and yield from
a controlled ﬂock, a chicken farm was built, equipped and validated
for full biosafety procedures. The farm comprises a 300 m2 storage
house with cages for chickens up to 4 months old, and a 1000 m2
laying house for a maximum capacity of 7000 chickens over 4
months old. A pest and insect control system and a small labora-
tory to control the ﬂock are also in place. Breeding was  initiated in
August 2010 following receipt of 3500 one-day-old chickens from
France. Pending the availability of eggs from the IVAC farm in early
2011, eggs are being sourced from the Ministry of Agriculture under
a protocol agreement to guarantee ample quantities under proper
procedures. Chicken feed is supplied by a recognized company in
Viet Nam to assure the quality and yield of eggs. Once fully oper-
ational, IVAC will be the sole qualiﬁed clean egg producer in Viet
Nam, and will serve as a source for other national and potentially
United Nations institutions.
The  Ministry of Agriculture inspected the set up at regular
intervals and following a successful audit, the facility, equipment
and procedures of the chicken farm have been validated and doc-
umented within a maintenance programme, including standard
operating procedures and training for personnel.
5. Skills development
IVAC  has a history of compliance to GMP  and ISO 9001 qual-
ity standards for its marketed products. For the inﬂuenza vaccine
project, IVAC has beneﬁted from the WHO  collaboration to enhance
the skills of its production and quality assurance and control staff.
To date, four quality control staff from IVAC have been trained at the
National Institute for Biological Standards and Control (NIBSC) dur-
ing 1–2 week courses, and two quality assurance and six production
n between nozzle depth and harvest yield.
g) Bottle empty (g) Harvest (g) Harvest (g/egg)
1563.0 1662.0 11.54
1512.5 1789.3 12.43
1543.5 2201.1 15.29
1554.1 2131.7 14.80
1559.8 2219.1 15.41
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taff were trained at NVI. These courses provided advice and hands-
n experience in quality processes and procedures, laboratory and
roduction scale process development and validation, and GMP
roduction. In addition, a three-year consultancy agreement has
een signed with NVI to cover the production process of egg-based
nﬂuenza vaccine in IVAC’s new facility, including on-site process
alidation, quality control and assurance, efﬁcacy monitoring and
pre)clinical trials.
IVAC  staff have also been trained in the installation, opera-
ion and maintenance of equipment by the relevant suppliers,
long with concepts of safety and biosecurity related to speciﬁc
achinery and for the chicken farm. Key personnel responsible
or managing the chicken farm have also been trained in chicken
usbandry by the Ministry of Agriculture in Hanoi.
. Discussion
Applying our extensive knowledge in the manufacture and
uality control of vaccines to published data, we  succeeded in
eveloping an A(H5N1) candidate vaccine in our research labora-
ory and have made signiﬁcant progress over the last two  years
owards our goal to produce a pandemic inﬂuenza vaccine for
he Vietnamese market. We  have built, equipped and expanded
 manufacturing facility to be able to produce >1 million doses
er year as well as an operational poultry farm without the sup-
ort of technology partner, and with only US$3.5 million seed
unding from WHO  to supplement the US$ 300 000 we were able
o invest from our own funds. We  have also managed to meet
ur original time frame despite challenges posed, for example, by
he delayed arrival of funds and import authorization for materi-
ls.
By January 2011, when eggs from our chicken farm become
vailable, we will initiate clinical studies to develop H1N1 and
5N1 vaccines. Subject to satisfactory results, IVAC plans to apply
or registration and licensing of a monovalent H1N1 vaccine by the
nd of 2012, followed shortly afterwards by a monovalent H5N1
accine. At least 200,000 doses of H1N1 and 500,000 doses of H5N1
nﬂuenza will be stockpiled in 10-dose vials for essential popula-
ions in Viet Nam (elderly, health-care workers, pregnant women
nd persons at higher risk).IVAC  has decades of experience of working with leading vac-
ine R&D entities from all continents. A welcome effect of the WHO
roject has been interest from further international partners to
upport our research and expand our skills. We  were selected, forS (2011) A34– A36
example, as part of a grant from the USA to support, in particular,
environmental aspects of our pandemic inﬂuenza project, and the
development of Phases I and II safety and immunogenicity studies
in human clinical trials of our vaccine. To this end a gap analysis
was carried out during an on-site mission from PATH on outstand-
ing measures needed to meet GMP  quality clinical trial materials
and biosafety standards. All elements of the gap analysis have been
implemented satisfactorily. We  also signed a protocol agreement in
January 2010 with the Scientiﬁc Research Institute of Inﬂuenza of
the Russian Academy of Medical Science for the joint development
of vaccines, including clinical trials and adjuvants, as a strategic
defence against highly pathogenic avian inﬂuenza virus.
The  Government has been very supportive of IVAC’s work,
exempliﬁed by the announcement of our WHO  grantee status by
the Prime Minister in January 2008. In addition, the Government
has supported the development of A(H5N1) and A(H1N1) vaccines
which, subject to successful testing, will enter production in Viet
Nam in 2011 for free distribution to populations at high risk. The
establishment of a seasonal inﬂuenza programme targeting the
same population groups is also under consideration, which would
ensure the sustainability of inﬂuenza vaccine manufacture in Viet
Nam.
The fundamental strengths of IVAC in quality control and tech-
nology management, backed by its international partners, will
assure the successful development and licensing of a pandemic
inﬂuenza vaccine for the population of Viet Nam.
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